Attendees at SLEEP 2026 in Baltimore can connect with industry representatives in the exhibit hall, where companies will showcase the latest products, technologies, and services shaping sleep medicine. The exhibit hall offers an opportunity to explore new solutions, ask questions, and interact directly with experts across the field.
The exhibit hall will be open Monday and Tuesday from 10 a.m. to 4 p.m. and Wednesday from 10 a.m. to 1:30 p.m. Attendees are encouraged to use the midday break starting Monday to visit exhibitors, connect with representatives, and purchase lunch from food kiosks available in the hall.
Additionally, check out the schedule of Industry Product Theaters and Industry Supported Events happening during SLEEP 2026 for more presentations and programs hosted by exhibitors and members of industry.
The following roundup highlights recent press releases from exhibiting companies, providing a preview of innovations on display and helping you plan your visit.
Alkermes to present new data on Alixorexton and Lumryz (sodium oxybate) at SLEEP 2026, highlighting breadth of sleep medicine research
Alkermes will present 26 abstracts, including posters featuring Lumryz (sodium oxybate) extended-release oral suspension, now part of Alkermes’ sleep portfolio following the acquisition of Avadel Pharmaceuticals earlier this year, and alixorexton, Alkermes’ novel, investigational, oral, selective orexin 2 receptor agonist in development for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Apnimed announces upcoming oral presentation at SLEEP 2026 to highlight pooled phase 3 data for AD109 in obstructive sleep apnea
Apnimed, Inc. announced that six abstracts have been selected for presentation, including an oral presentation, at SLEEP 2026. Certain abstracts will feature a pooled analysis of the SynAIRgy and LunAIRo Phase 3 trials of AD109, Apnimed’s lead product candidate, reflecting one of the largest clinical development programs conducted for obstructive sleep apnea pharmacotherapy. Other research underscores substantial unmet needs in OSA.
Pineapples, people, presentations, and possibilities: Join EnsoData at SLEEP 2026!
Join EnsoData at booth 219 meet the team, get personalized demonstrations of EnsoData products, view a variety of 15-minute presentations, and snag some pineapple swag. Beyond the booth, EnsoData is proud to have five abstracts accepted for SLEEP 2026. Make sure to visit the poster hall to chat with EnsoData’s research team about the latest deep-learning and AI discoveries.
Harmony Biosciences announces poster presentations at 2026 SLEEP annual meeting
Harmony Biosciences Holdings, Inc. announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026. View the poster presentation details.
Jazz Pharmaceuticals to present comprehensive data at SLEEP 2026 highlighting broad treatment effects of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for people with narcolepsy and idiopathic hypersomnia
Jazz Pharmaceuticals will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia.
Meet Nox at SLEEP 2026 and discover what’s next
Nox Medical invites you to booth #645 to experience its portfolio of sleep diagnostics solutions. This year, Nox Medical will host a satellite symposium titled “Endotyping Sleep Apnea: Precision Treatment in a Changing Therapeutic Landscape.” Nox Medical is also proud to contribute six accepted abstracts to the scientific program at SLEEP 2026 through a series of poster presentations. Finally, wrap up a busy day with Nox Night, a social event bringing together sleep industry professionals in a relaxed, upbeat atmosphere.
Onera will showcase its Onera hPSG solution at the SLEEP 2026 conference June 14-17, 2026, in Baltimore
Onera Health announced that its end-to-end home polysomnography solution, the Onera hPSG solution, will be featured in multiple scientific presentations at SLEEP 2026. The medtech company will showcase this innovative solution at booth #600. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium, “Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testing,” on Monday, June 15.
Resmed at SLEEP 2026: Advancing sleep health through innovation in screening, diagnosis and personalized care
Resmed announced it will present new research at SLEEP 2026, including 13 research abstracts exploring the future of sleep health and highlighting new data on obstructive sleep apnea screening, diagnosis and personalized care. Attendees are invited to visit booth #519 to explore Resmed’s portfolio of diagnostic and treatment solutions. Featured technologies include Somnoware, myAir and EasyCare Tx 2 sleep lab solution. Additionally, Resmed will post an Industry Product Theater, “Consumer Wearable Technologies as a Clinical Megatrend,” on Monday, June 15 at 11:45 a.m.
Sleep.ai to present 10 scientific studies at SLEEP 2026, highlighting advances in digital sleep intelligence and product validation
Sleep.ai announced that 10 scientific studies involving the company’s research and validation work will be presented at SLEEP 2026. The presentations include three original Sleep.ai-led AI/ML analyses and seven product validation studies conducted in collaboration with partners, reflecting the company’s continued investment in scientific rigor and evidence-based sleep innovation.
Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase 3 AWAKE narcolepsy study at SLEEP 2026
Suven Life Sciences will present three posters at SLEEP 2026. The presentations will showcase the clinical advancement of Samelisant (SUVN-G3031), including positive Phase 2 efficacy data in excessive daytime sleepiness, the rationale and design of a Phase 2 study for cataplexy in type 1 narcolepsy, and the Phase 3 development strategy for Samelisant in patients with narcolepsy (AWAKE study).
Wesper to unveil first multi-tier sleep diagnostic ecosystem for personalized sleep care at SLEEP 2026
Wesper will unveil its multi-tier sleep diagnostic ecosystem at SLEEP 2026. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right patient without changing how their clinic works. Wesper will demo both products at booth #1007 at SLEEP 2026.
